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Aim: Deregulation of microRNA has been associated with cancer progression and the modification of cancer phenotypes 
could be achieved by targeting microRNA expression. This study aimed to determine the effects of miR-372 on cell progression and 
gene expression in nasopharyngeal carcinoma cell line, TW01. Materials and Methods: NPC TW01 cells were transfected with 
the miR-372 precursor molecules. Gene expression studies were conducted using RT-PCR assays for nine cancer related genes. 
The effects of miR-372 on cell proliferation, cell cycle arrest and apoptosis were also investigated. Results: Expression 
of  miR-372 caused cell cycle arrest at the S phase that was accompanied by an overall decrease of cells entering the G2/M phase. 
miR-372 did not have any significant effect on apoptosis. Of the nine genes studied, four were up-regulated, namely CDKN1A, 
INCA1, LATS2 and BIRC5. The other five genes — CDK2, CCNA1, TP53, BAX and BCL2 were down-regulated by miR-372. 
Conclusion: This preliminary study indicated the tumor suppressing roles of miR-372 in cell cycle progression of TW01 cells, pos-
sibly via the down-regulation of CDK2 and CCNA1 as well as the up-regulation of CDKN1A and INCA1.
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Nasopharyngeal carcinoma (NPC) is common in areas 
such as Southern China and South East Asia. Popula-
tions originating from Hong Kong, Guangdong, Hainan, 
Guangxi, Hunan and Fujian Province have shown espe-
cially high incidence rates of NPC [1, 2]. In year 2007, NPC 
was recorded as the fourth most common cancers in Ma-
laysia with a total of 900 cases registered with the National 
Cancer Registry. The Age-standardised Incidence Rate 
(ASR) for male was 6.4 and 2.3 per 100.000 population 
for males and females, respectively [3].
MicroRNAs (miRNAs) are 21 to 25 nucleotides small 
RNAs which function as gene regulators by pairing 
to the target mRNAs to execute post-transcriptional re-
pression by either degradation of target mRNA or by pre-
venting protein translation [4]. Although many human 
miRNAs have been discovered [5], the roles of most 
miRNAs remain unknown. Dysregulation of miRNAs 
could lead to great regulatory upheavals in the cell, per-
haps leading to carcinogenesis [6]. For example, down-
regulation of let-7 and miR-26a in NPC cells resulted 
in cell proliferation through up-regulation of c-Myc [7] 
and EZH2 [8], respectively. Down-regulation of miR-29c 
caused up-regulation of genes encoding extracellular 
matrix proteins which are associated with increased 
invasiveness and metastasis of NPC [9]. In addition, ex-
pression of miR-155 caused down-regulation of JMJD1A, 
which leads to poor prognosis of NPC patients [10].
miR-372 showed dual roles on cancer cells,  acting 
as a tumor promoter as well as a tumor suppressor. To-
gether with the oncogenic RAS, miR-372 allowed cell 
proliferation and stimulated neoplastic transformation phe-
notype although wild type p53 was activated with induction 
of p21cip1 [11]. Presence of miR-372 caused cells to be in-
sensitive to the cell cycle inhibitor and the CDK activity was 
not inhibited [11]. In AGS human gastric adenocarcinoma 
cell line, miR-372 played an oncogenic role in regulating cell 
proliferation, cell cycle and apoptosis via down-regulation 
of its target gene, LATS2 [12]. Expression of LATS2 re-
sulted in the CDK inhibition and suppression of cell growth 
by blocking the G1/S transition [13]. On the contrary, 
miR-372 was found down-regulated in cervical carcinoma 
tissues and its expression down-regulated CDK2 and Cyclin 
A1 (CCNA1) resulted in the growth inhibition of HeLa cells 
and cell arrest in the S/G₂ phase [14]. In NPC TW01 cells, 
it was reported that miR-372 was down-regulated more 
than ten-fold in the presence of transforming growth factor 
beta 1 (TGF-β1) [15]. However, the roles of miR-372 in NPC 
have not been documented. Therefore, the present study 
aims to elucidate the role of miR-372 in NPC cell line, TW01.
MATERIAL AND METHODS
Transfection of miRNA-372 precursor into 
TW01 cells. NPC cell line, TW01 cells were cultured 
with DMEM/F12 (Invitrogen, USA) supplemented 
with 10% (v/v) fetal bovine serum (FBS). Transfection 
of Pre-miR™ hsa-miR-372 miRNA precursor molecules 
(Ambion, USA) into TW01 cells was carried out as de-
scribed by the manufacturer’s instruction using si-
PORT™ NeoFX™ Transfection Agent (Invitrogen, USA). 
The transfected cells were incubated in 5% CO2 tissue 
culture incubator at 37 °C for 72 h. The same proce-
dure was repeated for control (or untransfected TW01) 
where by miR-372 precursor in the transfection com-
plexes was replaced with nuclease-free water.
MicroRNA isolation and MicroRNA assay. In or-
der to determine the level of miR-372 in the transfected 
cells, miRNA was isolated from the transfected and 
untransfected TW01 cell using MirVanaTM miRNA 
Isolation Kit (Ambion, USA). The isolated miRNA was 
converted to cDNA using TaqMan® MicroRNA Reverse 
Transcription Kit (Applied Biosystems, USA) via MyCy-
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cler Thermal Cycler (Bio-Rad, USA). The level of miR-
372 in transfected cells was determined by conducting 
quantitative real-time PCR in the iQ5-Cycle (Bio-Rad, 
USA) using TaqMan® MicroRNA Assay and TaqMan® 
Fast Advanced Master Mix from Applied Biosystems, 
USA. The fold change was calculated based on ΔΔCT 
and SNORD44 was used for normalisation.
Cell progression assays. Transfected and un-
transfected (control) TW01 cells were subjected to cell 
progression assays, namely cell proliferation, cell cycle 
analysis and apoptosis assay. Cell proliferation assay was 
conducted using CellTiter 96® AQueous One Solution 
Cell Proliferation Reagent (Promega, USA) and absor-
bance was measured at a wavelength of 490 nm using 
a microplate reader (Opsys, Dynex Technologies, USA).
For cell cycle analysis, the cells were fixed with 70% 
ethanol (v/v) (Merck, USA) for a week at 4 °C and rinsed 
twice with PBS. A solution containing RNase A (Sigma-
Aldrich, USA) and propidium iodide (Sigma-Aldrich, 
USA) was added and the mixture was left in the dark 
for 30 min at room temperature. Cell cycle analysis 
was performed using a FACSCalibur flow cytometer 
(BD Biosciences, USA) which measured the cell fluo-
rescence at 536 nm excitation and 617 nm emissions.
In order to determine the apoptotic effect of miR-
372 on TW01 cells, transfected and untransfected cells were 
induced to undergo apoptosis by adding Staurosporine 
(Sigma-Aldrich, USA). The cells were incubated at 37 °C for 
3 h and subjected to the Caspase 3 Assay (Sigma-Aldrich, 
USA). Absorbance was measured at 405 nm using a micro-
plate reader (Tecan, Switzerland). The final concentration 
of the pNA released was calculated based on the p-Nitro-
aniline standard curve. The apoptotic index of the trans-
fected and untransfected TW01 cells was calculated as fol-
lows: apoptosis index = pNA induced/ pNA non-induced.
Gene expression assays. Gene expression assays 
were conducted for nine genes with primers purchased 
from Applied Biosystems, USA (Table). RNA was extracted 
from transfected and untransfected TW01 cells using 
RNeasy Mini Kit (Qiagen, Germany). RNA quantification was 
performed using NanoQuant™ (Tecan, Switzerland). Gene 
expression assay was performed using TaqMan® RNA-to-
CT™ 1-Step Kit (Applied Biosystems, USA) via the iQ5-
Cycle (Bio-Rad, USA). The fold change was calculated 
based on ΔΔCT and GAPDH was used for normalisation.
Table. List of genes studied for gene expression in TW01 cells using Taq-
man primers from Applied Biosystems (USA)
Genes Description (Taqman primer code)
CDK2 Cyclin-dependent kinase 2 (Hs01548894_m1)
CDKN1A Cyclin-dependent kinase inhibitor 1A (Hs00355782_m1)
CCNA1 Cyclin A1 (Hs01652223_m1)
INCA1 Inhibitor of CDK, cyclin A1 interacting protein 1 (Hs00171105_m1)
TP53 Tumour protein p53 (Hs01034249_m1)
LATS2 Large tumour suppressor, homologue 2 (Hs00324396_m1)
BAX B-cell CLL/lymphoma 2 — associated X protein (Hs00180269_m1)
BCL2 B-cell CLL/lymphoma 2 (Hs00608023_m1)
BIRC5 Baculoviral IAP repeat containing 5 (Hs00153353_m1)
Statistical analysis. All statistical analyses were 
performed using the software SPSS 17.0 (SPSS Inc., 
USA). Student t-test was used to analyze data of cell pro-
liferation and apoptosis assays whereas Mann — Whitney 
U test was used to analyze data of cell cycle analysis.
RESULTS AND DISCUSSION
Based on the results obtained from the TaqMan® Mi-
croRNA Assay, the level of miR-372 in transfected TW01 cells 
was determined to be more than 100.000 folds compared 
to untransfected cells. The high level of miR-372 caused 
significant decrease in cell proliferation of TW01 cells 
(p < 0.001, Fig. 1). As shown in Fig. 2, high level of miR-
372 resulted in significant increase of cells at the S phase 
(1.74%, p ≤ 0.05) and a reduction of cells in both 
the G2/M phase (1.97%, p ≤ 0.05) and the G0/G1 phase 
(0.75%, p > 0.05). A slight decrease in apoptotic index was 
observed in TW01 cells transfected with miR-372, however, 
it was not statistically significant (p > 0.05, Fig. 3).
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Fig. 1. Effects of miR-372 on cell proliferation of NPC TW01 cells. 
Cells were transfected with miR-372 precursor. Control consisted 
of TW01 cells exposed to transfection agent without the presence 
of miR-372 precursor. Cell proliferation assay was conducted  using 
CellTiter 96® AQueous One Solution Cell Proliferation Reagent 
(Promega, USA) as described in the Methodology. Statistical 
analysis was conducted using student t-test. *p ≤ 0.001 (n = 9)
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Fig. 2. Effects of miR-372 on cell cycle progression of TW01 cells. 
Cell cycle analysis was done using propidium iodide staining 
coupled with flow cytometry as described in Methodology. 
Statistical analysis was conducted using the Mann — Whitney 
U test. *p ≤ 0.05 (n = 3)
Fig. 4 shows that four genes, namely CDKN1A, INCA1, 
LATS2 and BIRC5 were up-regulated in the transfected 
TW01 cells as compared to untransfected cells.  However, 
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five genes including CDK2, CCNA1, TP53, BAX and 
BCL2 were down-regulated by miR-372. miR-372 was 
reported to target both CDK2 and CCNA1 by direct binding 
to their 3’UTR regions [14]. Down-regulation of both genes 
might lead to the significant decrease in TW01 cell prolifera-
tion as well as S phase cell arrest, observed in the present 
study. CCNA1 and CDK2 were reported to function as acti-
vators of transcription factor E2F1, which plays a critical role 
in the expression of genes required for cell progression [16]. 
E2F-mediated transcription could be repressed by retino-
blastoma protein (pRB), a tumor suppressor protein which 
inhibitory effect could be abolished by its phosphorylation 
with CCNA1/CDK2 [17]. Moreover, our observations were 
consistent with the report by Tian et al. [14] which stated 
that the expression of miR-372 in HeLa cells caused cell 
arrest at S phase and a decreased entrance of cells into 
G2/M phase via the down-regulation of CDK2 and CCNA1. 
Hence, this indicating that both CCNA1 and CDK2 were 
targets of miR-372 in NPC TW01 cells.
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Fig. 3. Effects of miRNA-372 on apoptosis of TW01 cells. Apop-
tosis was induced by adding staurosporine. Cells were subjected 
to the caspase 3 assay and the apoptotic index of the transfected 
group as well as the untransfected TW01 cells was calculated as de-
scribed in Methodology. Statistical analysis was conducted using 
student t-test (n = 9)
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Fig. 4. Effects of miR-372 on the expression of CDK2, CDKN1A, 
CCNA1, INCA1, TP53, LATS2, BAX, BCL2 and BIRC5 in TW01 cells. 
The CT values of each genes obtained from qRT-PCR were nor-
malised against housekeeping GAPDH. Fold change value greater 
than zero indicates up-regulation of gene whilst value lesser than 
zero indicates down-regulation of gene
It was interesting to note that LATS2 was up-regulated 
(11.29-fold) in TW01 cells when transfected with miR-
372 precursors, although LATS2 was reported as a target 
of miR-372 in human testicular germ cell tumors [11], gas-
tric adenocarcinoma [12], and colorectal carcinoma [18]. 
In addition, LATS2 was also reported to be associated with 
pRB-induced silencing of E2F target genes [19]. Even 
though LATS2 has been reported to have tumor sup-
pressive roles [13, 20]; it was reported to induce tumori-
genesis of NPC [21]. Down-regulation of LATS2 in 5–8F 
and CNE2 cells caused the inhibition of growth, induction 
of apoptosis and S phase cell arrest, while expression 
of LATS2 in NP69 cells increased cell proliferation [21].
In addition, CDKN1A (or p21) and INCA1 were noted 
to be up-regulated in transfected TW01 cells. CDKN1A 
and INCA1 are known inhibitors to the Cyclin/CDKs com-
plexes [22, 23]. INCA1 binds to CDK1- and CDK2-bound 
cyclins via a cyclin interaction domain, which is important 
to regulate the CDK inhibitory and the proliferation inhibi-
tory activities [23]. CDKN1A is known to bind to CDK and 
directly inhibiting the activity of CDK on pRB, hence, pre-
venting the release of transcriptionally active E2F [24]. 
It was also reported that CDKN1A could affect E2F 
activity via a pRB-independent pathway [25]. Although 
TP53 was reported to initiate the transcription of p21, 
it was interesting to note that TP53 was down-regulated 
while p21 was up-regulated. This phenomenon was 
not unusual as the TP53-independent up-regulation 
of p21 has also been reported in the presence of tumor 
suppressor genes such as Chk2 [26] and PML [27].
Down-regulation of the tumor suppressor TP53 and pro-
apoptotic BAX gene as well as up-regulation of anti-apop-
totic gene (Survivin, BIRC5) were observed in the trans-
fected TW01 cells. TP53 exhibits anti-neoplastic activity 
through the induction of apoptosis. TP53 could increase 
the permeability of BAX protein into mitochondria and 
thus, leading to the apoptotic program [28]. BAX has 
been reported to be a death effector and it is needed 
to induce mitochondrial dysfunction and death [29]. 
On the other hand, BIRC5 which was up-regulated has 
been reported to be associated with distant metastasis 
and poor prognosis in NPC [30, 31]. It was noted that 
BIRC5 was up-regulated in the background of reduce 
population of cells in G2/M phase although BIRC5 has been 
reported to be expressed mostly at G2/M phase [32, 33]. 
At this point, we could not explain the mechanism that has 
resulted in this phenomenon, although it might be related 
to the CDK inhibition. It was reported that suppression 
of Thr34 phosphorylation of BIRC5 would abolish its anti-
apoptotic activity [34]. Loss of phosphorylation might result 
in dissociation of survivin-caspase 9 complexes, leading 
to apoptosis or death of cancer cells at mitosis [35]. Hence, 
in this study, high level of miR-372 did not cause any sig-
nificant effect on apoptosis (see Fig. 3). This observation 
might also be due to the down-regulation of BCL2 which 
is an anti-apoptotic gene. The death-protective activity 
of BCL2 is associated with an inhibition of cell progression 
due to a prolong duration of G1 phase. It was observed 
that cells which lacked BCL2 expression would die from 
any stage of the cell cycle in the presence of apoptotic 
agents [36]. It was reported that in advanced staged NPC 
patients, those with negative BCL2 expression had a bet-
ter disease-free survival rate as compared to patients with 
BCL2 positive tumors [37]. Therefore, it was suggested that 
the interaction between genes, namely TP53, BAX, BIRC5 and 
BCL2 could have antagonised and neutralised each  other [38], 
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thus  explaining the marginal change in apoptotic indices 
between the control and transfected TW01.
Finally, this study showed that expression of miR-
372 decreased cell proliferation and induced S phase 
cell cycle arrest in TW01 cells. These effects could per-
haps, be attributed to the down-regulation of CDK2 and 
CCNA1 by miR-372. There was no significant effect 
of miR-372 on the apoptosis of TW01 cells. The study 
provides a preliminary overview of the potential application 
of miR-372 in targeting CDK2 and CCNA1 in NPC.
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